Texas, 18th July 2018 – HeartSciences today announced that Business Fortune has named it among the 50 Smartest Companies of the Year 2018.
“Business Fortune 50 Smartest Companies of the Year 2018 program identifies companies that mastered the discipline of smartness and stood high among the crowd,” said Vinay Kumar, Editor-in-Chief of Business Fortune Magazine. The publication has selected HeartSciences based on its innovation, revenue growth, customer reviews and domain influence.
“We are honored to be recognized by Business Fortune as the one of the 50 Smartest Companies of the Year 2018,” said Mark Hilz, CEO at HeartSciences. “HeartSciences is working to bridge today’s “diagnostic gap” in cardiac care by providing low-cost effective solutions that help to identify patients prior to experiencing an adverse cardiac event, such as a heart attack.”
About HeartSciences
HeartSciences is advancing the field of electrocardiography through the application of wavelet signal processing and artificial intelligence to develop next generation ECG technology. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista wavECG Cardiac Testing Device is a 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to the proprietary informatics, the MyoVista wavECG device also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training as well as easy and intuitive use. The MyoVista wavECG device is not currently approved for sale or distribution in the United States and is not currently FDA cleared.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com.
